Shares of Angie’s List (NASDAQ:ANGI) reached a new 52-week low during trading on Thursday following insider selling activity, AR Network reports. The company traded as low as $11.85 and last traded at $12.14, with a volume of 443,523 shares. Angie’s List Inc (NASDAQ:ANGI) shares after opening at $12.29 moved to $12.42 on last trade day and at the end of the day closed at $12.09. Company price to sales ratio in past twelve months was calculated as 2.88 and price to cash ratio as 12.64. Angie’s List Inc (NASDAQ:ANGI) showed a negative weekly performance of -7.43%.
EarthLink (NASDAQ:ELNK) was upgraded by analysts at Thomson Reuters/Verus from a hold rating to a buy rating. Earthlink Holdings Corp (NASDAQ:ELNK) shares fell -3.14% in last trading session and ended the day on $3.39. ELNK return on equity ratio is recorded as -138.90% and its return on assets is -43.40%. Earthlink Holdings Corp (NASDAQ:ELNK) yearly performance is -34.68%.
KiOR (NASDAQ:KIOR) major shareholder Stuart Peterson sold 182,900 shares of KiOR stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $0.70, for a total transaction of $128,030.00. Following the sale, the insider now directly owns 251,522 shares of the company’s stock, valued at approximately $176,065. KiOR Inc (NASDAQ:KIOR) shares moved down -18.40% in last trading session and was closed at $0.384 while trading in range of $0.36 – $0.45 – KiOR Inc (NASDAQ:KIOR) year to date (YTD) performance is -77.38%.
Ventrus Biosciences, Inc. (NASDAQ:VTUS) announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). Ventrus Biosciences Inc (NASDAQ:VTUS) weekly performance is -8.70%. On last trading day company shares ended up $1.26. Ventrus Biosciences Inc (NASDAQ:VTUS) distance from 50-day simple moving average (SMA50) is -49.14%. Analysts mean target price for the company is $2.50.